Page last updated: 2024-10-25

deferoxamine and Benign Infantile Myoclonic Epilepsy

deferoxamine has been researched along with Benign Infantile Myoclonic Epilepsy in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andreoli, SP1
Dunn, D1
DeMyer, W1
Sherrard, DJ1
Bergstein, JM1

Other Studies

1 other study available for deferoxamine and Benign Infantile Myoclonic Epilepsy

ArticleYear
Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    The Journal of pediatrics, 1985, Volume: 107, Issue:5

    Topics: Aluminum; Anemia; Child; Deferoxamine; Epilepsies, Myoclonic; Humans; Kidney Failure, Chronic; Male;

1985